SCHEMBL4672402

SCHEMBL4672402

Cc1ccc(Cc2cc(C(=O)C=C(O)C(=O)O)c[nH]2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.39
DAO P14920 3/20 0.38
ALDH1A1 P00352 5/20 0.35
HTT P42858 4/20 0.35
LMNA P02545 3/20 0.34
AKR1C4 P17516 2/20 0.33
AKR1C3 P42330 2/20 0.33
AKR1C2 P52895 1/20 0.33
AKR1C1 Q04828 1/20 0.33
CTBP2 P56545 1/20 0.33
GPR84 Q9NQS5 1/20 0.33
NPSR1 Q6W5P4 3/20 0.33
HPGD P15428 2/20 0.33
PKM P14618 2/20 0.33
ATM Q13315 2/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
NLRP1 Q9C000 1/20 0.33
MEN1 O00255 1/20 0.33
NTSR1 P30989 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672398 1.00 SRD5A2 (0.39) SRD5A2DAOALDH1A1HTTLMNA
SCHEMBL4677395 0.88 KMT2A (0.45) ALDH1A1HTTLMNAAKR1C3MAPT
SCHEMBL4677401 0.88 KMT2A (0.45) ALDH1A1HTTLMNAAKR1C3MAPT
SCHEMBL4671116 0.88 HCAR2 (0.39) DAOALDH1A1LMNAMEN1KMT2A
SCHEMBL4671120 0.88 HCAR2 (0.39) DAOALDH1A1LMNAMEN1KMT2A
SCHEMBL4675004 0.87 ALDH1A1 (0.38) DAOALDH1A1LMNACTBP2NPSR1
SCHEMBL4679210 0.87 HRH3 (0.36) ALDH1A1TDP1
SCHEMBL4679215 0.87 HRH3 (0.36) ALDH1A1TDP1
SCHEMBL4675001 0.87 ALDH1A1 (0.38) DAOALDH1A1LMNACTBP2NPSR1
SCHEMBL4672130 0.86 KDM5A (0.41) DAOALDH1A1LMNACTBP2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 SRD5A2 371/4885DAO 661/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.